Forward P/S Multiple: Accuray Incorporated (ARAY)
Accuray Incorporated (ARAY) is implementing AI algorithms for adaptive therapy, stimulating demand. The company's expected P/S ratio reflects the price action, with the indicator currently standing at 0.00. Revenues are based on software and service maintenance, despite the high cost of producing accelerators. Meanwhile, fierce competition for clinic budgets and the risk of technological obsolescence are putting pressure on the issuer's market position.
Metric breakdowns and analytics for Accuray, Inc. (ARAY)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt level and financial liquidity data:
Total Debt to Capital Accuray Incorporated|ARAY - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Accuray Incorporated|ARAY - Company Cumulative Debt|Debt to Book Value Accuray, Inc.|ARAY - Company Long-Term Loans and Borrowings|Company Short-Term Debts Accuray Incorporated|Quick Liquidity accuray.com
- net income and valuation multiples indicators:
ARAY - Company Profit|Projected Future Earnings Accuray Incorporated|ARAY - Price to Earnings Ratio|Future Price to Earnings Accuray Inc.|ARAY - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Accuray, Inc.|ARAY - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Accuray Incorporated|ARAY - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months accuray.com|ARAY - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Accuray Incorporated
- total revenue and sales volume data:
Initial company analysis:Accuray (ARAY)
This indicator determines the market value of Accuray Incorporated (ARAY) relative to expected sales volume, allowing for an assessment of the degree of optimism priced in or the risk of overpayment. By analyzing the forward revenue multiple, an investor can see the stability of the capitalization of Accuray Incorporated (ARAY), which is supported by the patent protection of robotic radiation systems and the complexity of integrating equipment into medical infrastructure.
Key competitors
Forward P/S Multiple ONC (BeiGene)|HALO - Forward Price-to-Revenue Multiple|RevMed - Forward P/S Multiple|Ascentage Pharma Corp (AAPG) - Forward Price-to-Revenue Multiple|CGON (CG Oncology, Inc.) - Forward Price-to-Revenue Multiple|urogen.com (URGN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Bicara Therapeutics|PSNL: Forward Price to Sales|Forward P/S Multiple ERAS|Forward P/S Multiple Delcath Corp (DCTH)|Y-mAbs Therapeutics - Forward Price-to-Revenue Multiple|aurabiosciences.com (AURA) - Market Cap to Future Revenue Ratio|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales SLS (SELLAS Life Sciences)|ACTU: Forward P/S Multiple|CTOR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio TuHURA Biosciences Inc.|Market Cap to Projected Revenue TARA (protaratx.com)|Forward P/S Multiple FATE|Forward Price-to-Revenue Multiple aadibio.com WHWK|Price-to-Projected Revenue Ratio TScan Therapeutics, Inc. TCRX|Champions Oncology Inc (CSBR) - Market Cap to Future Revenue Ratio|XBIT - Price-to-Projected Revenue Ratio|Forward Price to Sales CVM (CEL-SCI Corporation)|OS Therapies (OSTX) - Price-to-Projected Revenue Ratio|Future Price to Revenue RADX (radiopharmtheranostics.com)|Price-to-Projected Revenue Ratio Artiva Biotherapeutics Inc.|Market Cap to Future Revenue Ratio Adlai Nortye Limited ANL|Price-to-Projected Revenue Ratio Veru Inc. (VERU)|TPST (tempesttx.com) - Forward Price to Sales|Forward P/S Multiple XLO (Xilio Therapeutics)|Forward P/S Multiple Renovaro Biosciences RENB|MURA: Forward Price-to-Revenue Multiple|Kairos Pharma Ltd - Price to Expected Revenue Ratio|OKUR: Forward P/S Multiple|Market Cap to Future Revenue Ratio CytoMed Therapeutics Limited (GDTC)|CRIS (Curis Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue APLM (Apollomics Corp)|Forward P/S Multiple THAR|Forward P/S Multiple advanbiomed.com (ADVB)|Price-to-Projected Revenue Ratio Genprex, Inc. GNPX|Forward Price to Sales CLDI|Sunshine Biopharma, Inc. - Forward P/S Multiple|XBIO - Forward P/S Multiple|SLRX (Salarius) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Kitov Pharma (PPBT)|AONC (American Oncology Network Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple beigene.com (BGNE)|Forward P/S Multiple CKPT|Forward P/S Multiple elevationoncology.com (ELEV)|Price-to-Projected Revenue Ratio iCAD ICAD|IKNA: Market Cap to Projected Revenue|Notable Labs, Ltd. - Forward P/S Multiple|Viracta Therapeutics (VIRX) - Forward Price-to-Revenue Multiple|MOR: Forward P/S Multiple|Market Cap to Future Revenue Ratio NAYA Biosciences Inc (NAYA)|Price-to-Projected Revenue Ratio Ascentage Pharma Group Ltd
